"SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients"

PHASE4CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

October 6, 2021

Study Completion Date

October 6, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

Pharmaceutical form: solution for injection Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: solution for injection Route of administration: subcutaneous

Trial Locations (42)

168

Investigational Site Number :3800002, Roma

2217

Investigational Site Number :0360001, Kogarah

2606

Investigational Site Number :0360006, Phillip

3010

Investigational Site Number :7560001, Bern

3053

Investigational Site Number :0360003, Carlton

4102

Investigational Site Number :0360007, Woolloongabba

14004

Investigational Site Number :7240006, Córdoba

18016

Investigational Site Number :7240004, Granada

18101

Investigational Site Number :3760005, Afula

20089

Investigational Site Number :3800005, Rozzano

28007

Investigational Site Number :7240008, Madrid

28922

Investigational Site Number :7240010, Madrid

29200

Investigational Site Number :2500001, Brest

29407

Investigational Site Number :8400008, Charleston

31059

Investigational Site Number :2500006, Toulouse

34239

Investigational Site Number :8400003, Sarasota

37075

Investigational Site Number :2760001, Göttingen

41013

Investigational Site Number :7240005, Seville

44093

Investigational Site Number :2500003, Nantes

46026

Investigational Site Number :7240002, Valencia

46713

Investigational Site Number :7840002, Abu Dhabi

46940

Investigational Site Number :7240003, Manises

48149

Investigational Site Number :2760004, Münster

48455

Investigational Site Number :2760005, Bad Bentheim

53100

Investigational Site Number :3800003, Siena

56126

Investigational Site Number :3800001, Pisa

60590

Investigational Site Number :2760002, Frankfurt am Main

72117

Investigational Site Number :8400012, North Little Rock

75014

Investigational Site Number :2500002, Paris

80230

Investigational Site Number :8400005, Denver

80907

Investigational Site Number :8400013, Colorado Springs

86100

Investigational Site Number :3800004, Reggio Calabria

88045

Investigational Site Number :2760006, Friedrichshafen

90274

Investigational Site Number :8400001, Rolling Hills Estates

91120

Investigational Site Number :3760003, Jerusalem

94063

Investigational Site Number :8400002, Redwood City

97504

Investigational Site Number :8400007, Medford

06129

Investigational Site Number :3800006, Perugia

08208

Investigational Site Number :7240001, Barcelona / Sabadell

Unknown

Investigational Site Number :7840001, Dubai

DY1 2HQ

Investigational Site Number :8260002, Dudley

EH16 4SA

Investigational Site Number :8260004, Edinburgh

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT04033367 - "SAR231893-LPS15497- Dupilumab Effect on Sleep in AD Patients" | Biotech Hunter | Biotech Hunter